Vaccines (Oct 2022)

Antibiotic-Free Nanoplasmids as Promising Alternatives for Conventional DNA Vectors

  • Negar Seyed,
  • Farnaz Zahedifard,
  • Sima Habibzadeh,
  • Roya Yousefi,
  • Mahya Sadat Lajevardi,
  • Elham Gholami,
  • Sima Rafati

DOI
https://doi.org/10.3390/vaccines10101710
Journal volume & issue
Vol. 10, no. 10
p. 1710

Abstract

Read online

DNA vaccines with their extraordinary properties are the best choice as vectors for subunit vaccines but are not in compliance with safety regulations, mainly because of the antibiotic resistance genes on their backbone. New generations of plasmids with minimum bacterial backbones are now developed as promising alternatives to pass the safety rules and be replaced for conventional plasmids. Here we have compared the nanoplasmid (with RNA-out selection system and professional HTLV-1 containing promoter) and the conventionally used pcDNA plasmid, as regards the transfection efficiency. The EGFP gene was cloned in both pcDNA-3.1+ and NTC9385R-MSC and transfected into COS-7 cells for expression evaluation by flow cytometry. Meanwhile, qPCR was used to analyze the EGFP mRNA copy numbers. It was concluded that the nanoplasmid, with its extraordinary properties, can be a tempting alternative to conventional pcDNA in equal or equimolar concentrations for vaccine design. These promising results can put DNA vaccines back into focus, especially regarding diseases controlled by robust cellular immune responses.

Keywords